Yahoo
NasdaqCM - Delayed Quote USD

Gyre Therapeutics, Inc. (GYRE)

6.86 +0.42 (+6.52%)
At close: September 4 at 4:00:01 PM EDT
6.86 0.00 (0.00%)
After hours: September 4 at 7:30:03 PM EDT
Trade GYRE on Coinbase
Chart Range Bar
Loading chart for GYRE
  • Previous Close 6.44
  • Open 6.44
  • Bid 4.74 x 200
  • Ask 8.28 x 200
  • Day's Range 6.41 - 6.89
  • 52 Week Range 5.44 - 9.42
  • Volume 56,021
  • Avg. Volume 75,973
  • Market Cap (intraday) 727.392M
  • Beta (5Y Monthly) 4.83
  • PE Ratio (TTM) --
  • EPS (TTM) -0.21
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.67

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

www.gyretx.com

625

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GYRE
2.83%
S&P 500 (^GSPC)
12.75%

1-Year Return

GYRE
9.50%
S&P 500 (^GSPC)
18.71%

3-Year Return

GYRE
1.63%
S&P 500 (^GSPC)
70.93%

5-Year Return

GYRE
37.41%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 29.11M
Earnings -10.61M
Profit Margin -36.44%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
0
10M
20M
30M
-30.0%
-20.0%
-10.0%
0.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

18.00
18.67 Average
6.86 Current
20.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/10/2025
Analyst Jefferies
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 16

Statistics

View More

Valuation Measures

Annual
As of 5/6/2026
  • Market Cap

    682.86M

  • Enterprise Value

    611.48M

  • Trailing P/E

    402.00

  • Forward P/E

    78.12

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.30

  • Price/Book (mrq)

    6.33

  • Enterprise Value/Revenue

    5.57

  • Enterprise Value/EBITDA

    131.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -19.33%

  • Return on Assets (ttm)

    -5.42%

  • Return on Equity (ttm)

    -17.44%

  • Revenue (ttm)

    109.82M

  • Net Income Avi to Common (ttm)

    -19.91M

  • Diluted EPS (ttm)

    -0.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    74.8M

  • Total Debt/Equity (mrq)

    2.07%

  • Levered Free Cash Flow (ttm)

    1.88M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

6.86 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: